Merck & Co., Inc.
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 12, 2025), Merck & Co., Inc. reported 13 stock positions worth $228.0 million. Its top holding was Personalis (PSNL) at 40.2% of the portfolio, followed by Moderna (MRNA, 26.1%) and Kymera Therapeutics (KYMR, 19.2%). Its holdings were unchanged from Q2 2025.
- Most Recent 13F
- Q2 2026
- Location
- RAHWAY, NJ
- CIK
- 0000310158
- Portfolio Value
- $228.0M (Q3 2025)
- SEC Filing
- 0000310158-25-000063 ↗ filed Nov 12, 2025
Holdings Value
Holdings 13 stocks · $228.0M
| PSNL Personalis Inc. | 40.16% | 14,044,943 | $91.6M | No change |
| MRNA Moderna Inc. | 26.15% | 2,308,190 | $59.6M | No change |
| KYMR Kymera Therapeutics Inc. | 19.17% | 772,165 | $43.7M | No change |
| ALEC Alector Inc. | 4.60% | 3,545,719 | $10.5M | No change |
| ENTRADA THERAPEUTICS INC | 4.43% | 1,739,768 | $10.1M | No change |
| EVAX Evaxion Biotech A/S | 2.00% | 1,214,126 | $4.6M | No change |
| STRO Sutro Biopharma Inc. Com SHS | 1.04% | 2,723,509 | $2.4M | No change |
| VRDN Viridian Therapeutics Inc. | 0.88% | 93,414 | $2.0M | No change |
| LVTX Lava Therapeutics NV | 0.79% | 1,149,345 | $1.8M | No change |
| XLO Xilio Therapeutics Inc. | 0.55% | 1,483,758 | $1.3M | No change |
| CARM Carisma Therapeutics Inc. | 0.18% | 1,473,240 | $404K | No change |
| NEUP Neuphoria Therapeutics Inc. | 0.05% | 10,027 | $118K | No change |
| HURA Tuhura Biosciences Inc. | 0.02% | 13,950 | $35K | No change |
Portfolio Sells Q2 2025 → Q3 2025
| None this quarter. | |||
Portfolio Buys Q2 2025 → Q3 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $526.4M | PSNL, MRNA, KYMR, AKTS, EIKN |
| Q1 2026 | 14 | $349.4M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN |
| Q4 2025 | 12 | $276.3M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX |
| Q3 2025 | 13 | $228.0M | PSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC |
| Q2 2025 | 13 | $215.6M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q1 2025 | 12 | $164.3M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q4 2024 | 13 | $258.0M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |